Erick Kipngetich Towett

Mr. Erick Kipngetich Towett

Upstream Petroleum, Energy and Petroleum Regulatory Authority Kenya, Nairobi, Nairobi City, Kenya
orcid
There is power in Research

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Erick Kipngetich TowettErick Kipngetich Towett
Erick Kipngetich Towett
JTJacqueline Tembu
Jacqueline Tembu
DKDouglas Kemboi
Douglas Kemboi
MLMoses Langat
Moses Langat
AMAmanda-Lee Ezra Manicum
Amanda-Lee Ezra Manicum
The use of metal-based complexes is currently taking centre stage in the field of nanomedicine for the treatment and control of various ailments. Rhenium(I) tricarbonyl complexes have frequently been evaluated in vitro for their anticancer activities, and a few have advanced to in vivo and clinical trials, owing to the distinct application characteristics of these complexes. Their inception in drug development is key. This study explores a detailed chronological overview of the medical applications of Re(I) tricarbonyl complexes over the past six years (2019–2024), focusing on their applications and clinical tests in the control and management of various ailments. An in-depth examination of their activities in anticancer treatments, Chagas disease, antifungal infections, antimalarial, and microbial infections was conducted, comparing the complexes to various standard antibiotics, conventional antimalarial drugs, antifungals, and standard anticancer agents.

31 May 2021 in Journal of Medicinal Plants Research
Verified
Journal Article
Open access
PDF file
Erick Kipngetich TowettErick Kipngetich Towett
Erick Kipngetich Towett
JJJepkorir Kiplimo Joyce
Jepkorir Kiplimo Joyce
MJMatasyoh Josphat
Matasyoh Josphat
Fungal endophytes are regarded as inexhaustible sources of pharmaceuticals and agrochemicals with profound antibacterial, anticancer or antifungal activities. Diaporthe sp., an endophytic fungus residing in medicinal plant S. cordatum, showed a good antagonism against bacterial pathogens of beans; Pseudomonas syringae pv phaseolicola (Psp) and Xanthomonas axonopodis pv phaseoli (Xap), with zones of inhibitions of 14.00 ± 1.15 and 17.00 ± 0.58 mm against the test organisms respectively. Large scale fermentation of Diaporthe sp. was performed on rice media after which ultrasonic extraction on methanol was done to yield methanol crude extract. Methanol crude extract was then partitioned between hexane and ethyl acetate to yield their respective crude extracts. Ethyl acetate fraction of Diaporthe sp. yielded one new naphthalene derivative compound which was accorded IUPAC name as 3-methoxy-5-methylnaphthalene-1, 7-diol after series of purifications on column chromatography as well as preparative high-performance liquid chromatography (pHPLC). Structure determination of isolated compounds was performed on 1D and 2D Nuclear Magnetic Resonance (NMR) spectroscopy experiments as well as a mass spectrometer to affirm its molecular mass. The F3 that yielded compound 1 had palpable antibacterial activities against Psp and Xap, with corresponding Minimum Inhibitory Concentration (MIC) values of 2.50 mg/ml (7.00 ± 0.00 mm) and 1.25 mg/ml (7.67 ± 0.33 mm) against the tests organisms respectively. These slight MIC values are chiefly attributed to the presence of active secondary metabolites in the fungal extracts that act against the test pathogens. This has therefore confirmed that fungal endophytes and their extractives have desirable antibacterial activities hence can be used in the formulation of agrochemicals or used as bio-control agents in crop protection especially in common beans (Phaseolus vulgaris L). Key words: Endophytes, Diaporthe sp, bean bacterial pathogens. Fungal endophytes are regarded as inexhaustible sources of pharmaceuticals and agrochemicals with profound antibacterial, anticancer or antifungal activities. Diaporthe sp., an endophytic fungus residing in medicinal plant S. cordatum, showed a good antagonism against bacterial pathogens of beans; Pseudomonas syringae pv phaseolicola (Psp) and Xanthomonas axonopodis pv phaseoli (Xap), with zones of inhibitions of 14.00 ± 1.15 and 17.00 ± 0.58 mm against the test organisms respectively. Large scale fermentation of Diaporthe sp. was performed on rice media after which ultrasonic extraction on methanol was done to yield methanol crude extract. Methanol crude extract was then partitioned between hexane and ethyl acetate to yield their respective crude extracts. Ethyl acetate fraction of Diaporthe sp. yielded one new naphthalene derivative compound which was accorded IUPAC name as 3-methoxy-5-methylnaphthalene-1, 7-diol after series of purifications on column chromatography as well as preparative high-performance liquid chromatography (pHPLC). Structure determination of isolated compounds was performed on 1D and 2D Nuclear Magnetic Resonance (NMR) spectroscopy experiments as well as a mass spectrometer to affirm its molecular mass. The F3 that yielded compound 1 had palpable antibacterial activities against Psp and Xap, with corresponding Minimum Inhibitory Concentration (MIC) values of 2.50 mg/ml (7.00 ± 0.00 mm) and 1.25 mg/ml (7.67 ± 0.33 mm) against the tests organisms respectively. These slight MIC values are chiefly attributed to the presence of active secondary metabolites in the fungal extracts that act against the test pathogens. This has therefore confirmed that fungal endophytes and their extractives have desirable antibacterial activities hence can be used in the formulation of agrochemicals or used as bio-control agents in crop protection especially in common beans (Phaseolus vulgaris L). Key words: Endophytes, Diaporthe sp, bean bacterial pathogens.

27 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Erick Kipngetich TowettErick Kipngetich Towett
Erick Kipngetich Towett
DKDouglas Kemboi
Douglas Kemboi
JTJacqueline Tembu
Jacqueline Tembu
MLMoses Langat
Moses Langat
AMAmanda-Lee Ezra Manicum
Amanda-Lee Ezra Manicum
The use of metal-based complexes is currently taking center stage in the field of nanomedicine for the treatment and control of various ailments. Rhenium(I) tricarbonyl complexes have frequently been evaluated in vitro for their anticancer activities, and a few have advanced to in vivo and clinical trials, owing to the distinct application characteristics of these complexes. Their inception in drug development is key. This study explores a detailed chronological overview of the medical applications of Re(I) tricarbonyl complexes over the past six years (2019-2024), focusing on their applications and clinical tests in the control and management of various ailments. An in-depth examination of their activities in anticancer treatments, Chagas disease, antifungal infections, antimalarial, and microbial infections was conducted, comparing the complexes to various standard antibiotics, conventional antimalarial drugs, antifungals, and standard anticancer agents.